Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer

Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer

Introduction: The effect of systemic administration of bevacizumab in cancer patients over a 5-year period after the beginning of chemotherapy treatment and comparison with a control group. Methods: The study population consists of adult patients with metastatic breast or colorectal cancer who had n...

Full description

Bibliographic Details
Main Authors:	Ioannis Kapelakis, Konstantinos Toutouzas, Maria Drakopoulou, Archontoula Michelongona, Flora Zagouri, Aristotle Mpamias, Paraskevi Pliatsika, Meletios-Athanasios Dimopoulos, Christodoulos Stefanadis, Dimitrios Tousoulis
Format:	Article
Language:	English
Published:	Elsevier 2017-05-01
Series:	Hellenic Journal of Cardiology
Subjects:	Bevacizumab Angiogenesis Cancer Coronary artery disease Vascular endothelial growth factor
Online Access:	http://www.sciencedirect.com/science/article/pii/S1109966616302366

Similar Items

Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018-08-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
by: Adam L. Cohen, et al.
Published: (2013-08-01)

The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea
by: Luiz F.M. Barros, et al.
Published: (2007-09-01)

A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
by: Soysal D., et al.
Published: (2014-12-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
by: Ananaya Datta-Mitra, et al.
Published: (2014-01-01)

In Vivo investigation of radiolabeled Bevacizumab in healthy rat tissues
by: Ilknur Demir, et al.
Published: (2011-02-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
by: N. García-Romero, et al.
Published: (2020-06-01)

Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical Trial
by: Mohammad-Reza Razeghinejad, et al.
Published: (2014-01-01)

A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
by: Gustavo Maluf, et al.
Published: (2019-10-01)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
by: Maria Kaparelou, et al.
Published: (2022-04-01)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
by: Neel Patel, et al.
Published: (2017-05-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
by: Eudocia Q. Lee, et al.
Published: (2019-10-01)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018-05-01)

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives
by: Klaudia Żak, et al.
Published: (2024-03-01)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
by: Chih-Lin Mao, et al.
Published: (2022-06-01)

Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
by: María Gaibar, et al.
Published: (2021-01-01)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
by: Liu J, et al.
Published: (2019-11-01)

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
by: Haiyan Jia, et al.
Published: (2021-10-01)

Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
by: Aysegül Tura, et al.
Published: (2019-06-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
by: Seung Won Choi, et al.
Published: (2018-05-01)

The Effect of Subconjunctival Bevacizumab on Angiogenesis in Rabbit Model
by: Nurwasis Nurwasis, et al.
Published: (2021-01-01)

A bilayer collagen scaffold with bevacizumab stabilizes chondrogenesis and promotes osteochondral regeneration
by: Xueyang Zheng, et al.
Published: (2022-09-01)

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2020-11-01)

Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy
by: Rahmawati Minhajat, et al.
Published: (2021-05-01)

Corrigendum: Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2021-02-01)

Anti-Vascular Endothelial Growth Factor (Bevacizumab) Therapy Reduces Hypertrophic Scar Formation in a Rabbit Ear Wounding Model
by: Do Hoon Kwak, et al.
Published: (2016-11-01)

Unlocking Bevacizumab’s Potential: rCBV<sub>max</sub> as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients
by: María del Mar Álvarez-Torres, et al.
Published: (2023-12-01)

Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer
by: Min Yan, et al.
Published: (2024-03-01)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
by: Sylvie Négrier, et al.
Published: (2017-08-01)

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
by: Varun Monga, et al.
Published: (2018-02-01)

Bevacizumab, a vascular endothelial growth factor inhibitor, promotes orthodontic tooth movement in an experimental rat model
by: Hatem Abuohashish, et al.
Published: (2023-05-01)

Fotocoagulación panretinal y bevacizumab intravítreo en el tratamiento de la retinopatía diabética proliferativa activa
by: Arianna Hernández Pérez, et al.

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
by: Lei Zhang, et al.
Published: (2019-04-01)

Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema
by: Sever Ozkan, et al.
Published: (2019-01-01)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
by: Antonia Martinetti, et al.
Published: (2014-08-01)

Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization
by: Ulrike Lessiak, et al.
Published: (2023-10-01)

Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies
by: Xiao Han, et al.
Published: (2023-07-01)

Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab
by: Tianshu Ren, et al.
Published: (2022-07-01)

Bevacizumab plus dacomitinib combination therapy for L858R‐mutated metastatic lung adenocarcinoma: A report of two cases
by: Chi‐Kang Teng, et al.
Published: (2022-05-01)